Literature DB >> 32509765

Ocular Surface Fibroma: Clinical, Histopathological, and Immunohistochemical Features of 10 Cases.

Hardeep Singh Mudhar1, Lindsay A McGrath2, Andy K K Chung3, Jeremy Bowyer4, Ian Rennie2.   

Abstract

AIM: To describe the clinical, histological, and immunohistochemical (IHC) features of a series of 10 cases of ocular surface fibroma (OSF) and correlate the findings with other similar histological entities.
METHOD: The patient demographics and features of the lesions were analysed from the clinical notes. All cases in the series had routine diagnostic excisional biopsies with standard histopathological and IHC evaluation. Each case was analysed by histology and immunohistochemistry with antibodies to: CD34, Factor XIIIa, desmin, smooth muscle actin, S100, Melan-A, β-catenin, neurofilament, and Ki67.
RESULTS: OSF occurred on the bulbar, tarsal, or forniceal conjunctiva, and typically presented as a white, pink, or yellow sheet-like or nodular lesion. The most common symptom was irritation or a foreign-body sensation. Lesions ranged in size from 4 to 13 mm. Only 1/10 cases showed a recurrence after an incomplete excision. Histologically, OSF comprised bland spindle cells in a collagen stroma. The spindle cells were CD34-positive (in 10/10 cases) and a smaller subset was positive for Factor XIIIa (6/10 cases). Normal resident spindle cells in the conjunctival stroma, Tenon's capsule, and tarsal plate were positive for CD34 and Factor XIIIa, implicating these cells in the origin of OSF.
CONCLUSION: OSF is a benign lesion of resident CD34- and Factor XIIIa-positive spindle cells in the conjunctiva and Tenon's capsule. We have called to attention another lesion to be included by clinicians in the differential diagnosis of benign ocular surface lesions composed of CD34- and Factor XIIIa-positive spindle cells.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  CD34; Conjunctiva; Factor XIIIa; Fibroblast; Fibroma; Mast cells; Ocular surface; Ocular surface fibroma; Plica; Tenon's capsule

Year:  2019        PMID: 32509765      PMCID: PMC7250335          DOI: 10.1159/000503360

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  9 in total

1.  Mast cell frequency in soft tissue tumors. Relation to type and grade of malignancy.

Authors:  K Donhuijsen; M Sastry; B Völker; L D Leder
Journal:  Pathol Res Pract       Date:  1992-02       Impact factor: 3.250

2.  Conjunctival stromal tumor: report of 4 cases.

Authors:  Martina C Herwig; Jill R Wells; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2011-12-24       Impact factor: 12.079

3.  Conjunctival Stromal Tumor.

Authors:  Erin L Greenberg; Edgar M Espana; Curtis E Margo
Journal:  Ophthalmology       Date:  2018-01       Impact factor: 12.079

Review 4.  The controversial role of mast cells in fibrosis.

Authors:  Peter Bradding; Gunnar Pejler
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

5.  Epibulbar fibroma of the conjunctival substantia propria.

Authors:  F A Jakobiec; E Sacks; R L Lisman; W Krebs
Journal:  Arch Ophthalmol       Date:  1988-05

6.  Tarsal fibroma.

Authors:  T J Clinch; D A Kostick; D M Menke
Journal:  Am J Ophthalmol       Date:  2000-05       Impact factor: 5.258

7.  Epibulbar subconjunctival fibroma. A tumor possibly arising from Tenon's capsule.

Authors:  B J Herschorn; F A Jakobiec; A Hornblass; T Iwamoto; W G Harrison
Journal:  Ophthalmology       Date:  1983-12       Impact factor: 12.079

8.  Conjunctival Stromal Tumor: Expansion of Findings in a Newly Described Entity.

Authors:  Claudia Auw-Haedrich; Katarzyna D Danielewicz; Pia R Mendoza; Thomas Reinhard; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2016-01-08       Impact factor: 12.079

9.  Conjunctival myxoid stromal tumour: a distinctive clinicopathological and immunohistochemical study.

Authors:  Xiao-Yi Qin; Zhe-Hao Jin; You-Pei Wang; Zong-Duan Zhang
Journal:  Br J Ophthalmol       Date:  2018-10-31       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.